Prof. Agnieszka Czechowicz is a physician-scientist and biotech entrepreneur with 20 years of experience in stem cell biology and translational research. Dr. Czechowicz is a faculty member in Stanford University?s Department of Pediatrics, Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine Division.
Dr. Czechowicz?s primary clinical interests are in bone marrow failure, aplastic anemia, and other diseases that necessitate stem cell transplantation. Her primary research interests are in transplantation, gene-therapy/gene-editing and regenerative medicine. Multiple pre-clinical and clinical therapies are in development based upon her studies.
Dr. Czechowicz?s pioneering work has led to critical developments within the life sciences ecosystem. She is the scientific co-founder of Magenta Therapeutics, and her inventions on antibody-based conditioning have also been licensed and are being pursued by Jasper Therapeutics and Forty Seven Inc (acquired by Gilead in 2020). Her efforts have also led to critical patents in development at Editas Medicine and Decibel Therapeutics. Previously, Dr. Czechowicz spent nearly a decade as a consultant at Third Rock Ventures, where she assisted and started companies including Global Blood Therapeutics, Bluebird Bio, Editas Medicine, Decibel Therapeutics and Magenta Therapeutics. She has also advised Beam Therapeutics and Spotlight Therapeutics.
Dr. Czechowicz completed her Ph.D. work in the stem cell biology at Stanford University with Prof. Irv Weissman. She then completed her residency in Pediatrics at the Boston Children?s Hospital, and subsequently pursued subspecialty training in Pediatric Hematology and Oncology at the Dana Farber Cancer Institute while simultaneously conducting postdoctoral research with Prof. Derrick Rossi in collaboration with Prof. David Scadden. She received her M.D., Ph.D., and Bachelor?s Degree from Stanford University.
Dr. Czechowicz is a strong physician-scientist and advocate of translational research. She has done pioneering work showing that hematopoietic stem cell depletion is a critical component to donor hematopoietic stem cell engraftment. She has also led several clinical trials exploring new treatments for Fanconi Anemia. She is passionate about mentoring and training future generations of physicians and scientists, and is very supportive of helping diverse trainees on various traditional and non-traditional career paths. Dr. Czechowicz can best be reached through her administrative assistant Beatrice Ochoa (email@example.com).
Recent press releases on her efforts can be found here:
Member, Stanford Institute for Stem Cell Biology and Regenerative Medicine (2018 - Present)
Member, Stanford Diabetes Research Center (2018 - Present)
Honors & Awards
Lorry I. Lokey Faculty Scholar, Stanford University School of Medicine ((2019-2024))
Clinical Fellowship III, Stanford University, Pediatric Hematology/Oncology/Transplant (2017)
Clinical Fellowship I-II, Dana Farber Cancer Institute, Pediatric Hematology/Oncology/Transplant (2016)
Clinical Residency, Boston Children's Hospital, Pediatrics (2014)
Irving L. Weissman, Agnieszka Czechowicz, Deepta Bhattacharya, Daniel Kraft. "United States Patent Application US12447634 Selective immunodepletion of endogenous stem cell niche for engraftment", Leland Stanford Junior University
Alexandra Glucksmann, Deborah Palestrant, Louis Anthony Tartaglia, Jordi Mata-Fink, Agnieszka Czechowicz, Alexis Borisy. "United States Patent Application US14536319 CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS", EDITAS MEDICINE Inc, University of Iowa Research Foundation (UIRF), Massachusetts Institute of Technology, Broad Institute Inc
David T. Scadden, Rahul Palchaudhuri, Derrick J. Rossi, Agnieszka Czechowicz. "United States Patent Application US15148837 Compositions and methods for non-myeloablative conditioning", President And Fellows Of Harvard College, The General Hospital Corporation, The Children's Medical Center Corporation
Albert Edge, Michael Venuti, Agnieszka Czechowicz. "United States"United States Patent Application US62288958 Expansion and differentiation of inner ear supporting cells and methods of use thereof"", Massachusetts Eye and Ear Infirmary, Decibel Therapeutics